NEWS & INSIGHTS
Site visits pose many problems for clinical trial sponsors, especially during the ongoing pandemic. However, research can continue with minimized risk for all involved when done virtually.
ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients
ObvioHealth, a full-service virtual research organization (VRO), announces today a partnership with La Foundation Hôpital Paris Saint Joseph to monitor COVID-19 prevalence and symptoms among the oncology patients of the Groupe Hospitalier Paris Saint Joseph.
COVID-19 drug development has brought a unique set of clinical challenges, virtual patient training and decentralized trials can be part of the solution.
ObvioHealth, a leading virtual health research organization or VRO, announced today it has raised $17 million in its latest round of financing. This round of financing comes on the heels of a global alliance with a strategic partner announced in March.
Singapore and New-York, 2 April 2020 – ObvioHealth, a digital research company, announces the launch of a registry to monitor COVID-19 prevalence, symptoms and immune response in the United States over the coming 12 months.
ObvioHealth is excited to announce the completion of enrollment for its latest completely virtual research study. Our digital, disruption-free, approach to recruitment allowed participants to enroll from the safety of their homes.
Medical personnel working on the frontline to prevent the spread of the COVID-19 (coronavirus) are susceptible to infection, we believe telemedicine can help to mitigate this risk.
A research study designed around the needs of its participants is more likely to deliver better data, a product of optimized compliance and engagement. By pairing a versatile digital solution with an accommodating protocol design, ObvioHealth can offer maximum convenience to those who matter most: the people who produce the data. The result? A collection of real-world data points and enhanced insights.
In the clinical trial space, patient concerns that must be addressed with tact. Whether delivering potentially life-altering news, or discussing a health-related concern, I find digital interaction to be the most prudent approach to sustaining engagement and reducing dropout. Here are five real-life examples of this strategy at-work.
The U.S. FDA is aware the drug approval process can often be strenuous, consuming large amounts of time and money. That’s why they’ve made a commitment to consider real-world evidence in the approval of new drug indications resulting in a more efficient approach for manufacturers.
A multinational food and beverage corporation offering a line-up of brands under the dairy/plant-based, and specialized nutrition categories sought to analyze the prevalence of specific functional gastrointestinal disorders (FGIDs) in infants and toddlers.